公开(公告)号：US10696677B2

公开(公告)日：2020-06-30

申请号：US16472155

申请日：2017-12-20

Applicant: Research Triangle Institute

Inventor： Rangan Maitra ,  Robert W. Wiethe ,  Yanan Zhang ,  George S. Amato

IPC: C07D473/34 ,  C07D471/10 ,  A61K31/52 ,  A61P1/16

Abstract: This disclosure is directed to various compounds and methods of preparation of improved compounds that are capable of functioning as cannabinoid receptor 1 (CB1) antagonists with reduced central nervous system (CNS) side effects. The application is also directed to pharmaceutical compositions containing one or more of these compounds, which may also contain one or more additional therapeutic agents. It is also directed to methods of treatment of various conditions that may be responsive to antagonism of the CB1 receptors, including, but not limited to, metabolic syndromes (including liver disease, obesity, and diabetes).

公开(公告)号：US20190352305A1

公开(公告)日：2019-11-21

申请号：US16472155

申请日：2017-12-20

Applicant: Research Triangle Institute

Inventor： Rangan Maitra ,  Robert W. Wiethe ,  Yanan Zhang ,  George S. Amato

IPC: C07D473/34 ,  C07D471/10

Abstract: This disclosure is directed to various compounds and methods of preparation of improved compounds that are capable of functioning as cannabinoid receptor 1 (CB1) antagonists with reduced central nervous system (CNS) side effects. The application is also directed to pharmaceutical compositions containing one or more of these compounds, which may also contain one or more additional therapeutic agents. It is also directed to methods of treatment of various conditions that may be responsive to antagonism of the CB1 receptors, including, but not limited to, metabolic syndromes (including liver disease, obesity, and diabetes).